Overview

This trial has been completed.

Condition osteoarthritis, knee
Treatments celution device, placebo
Phase phase 2
Sponsor Cytori Therapeutics
Start date January 2015
End date June 2016
Trial size 94 participants
Trial identifier NCT02326961, ACT-OA Knee

Summary

The primary objective of this study is to evaluate the safety and feasibility of intraarticular injection of Celution prepared adipose-derived regenerative cells injected into knees of patients with chronic knee pain due to osteoarthritis.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking double blind (subject, caregiver, investigator, outcomes assessor)
Primary purpose treatment
Arm
(Experimental)
Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration
celution device
ADRCs Prepared using the Celution Device
(Experimental)
Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration
celution device
ADRCs Prepared using the Celution Device
(Placebo Comparator)
Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.
placebo
Inactive Placebo

Primary Outcomes

Measure
Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain on Walking
time frame: 12 Weeks

Secondary Outcomes

Measure
Observed Pain Scores on 50-foot Walk Test
time frame: 48 Weeks
Number of Observed OARS130 Responders
time frame: 48 Weeks
Knee Injury and Osteoarthritis Outcome Score (KOOS)
time frame: 48 Weeks
VAS Assessments
time frame: 48 Weeks
Patient Global Assessment
time frame: 48 Weeks
Use of Rescue Medication
time frame: 48 Weeks
SF-36 Questionnaire
time frame: 48 Weeks
MRI Osteoarthritis Knee Score
time frame: 48 Weeks

Eligibility Criteria

Male or female participants from 40 years up to 69 years old.

Inclusion Criteria: 1. Males or females ≥ 40 and < 70 years of age 2. Able to provide written informed consent 3. Diagnosis of osteoarthritis in one or both knees by American College of Rheumatology (ACR) criteria 4. Kellgren and Lawrence grade 2 or 3 (standing AP x-ray) of the target knee within the preceding 6 months 5. Pain due to osteoarthritis in the target knee ≥ 6 months 6. Minimum score of "moderate" from KOOS question about pain on walking on a flat surface. 7. Minimum score of "moderate" from KOOS question about degree of difficulty during walking on a flat surface. 8. Continued knee pain and limitations in knee function despite prescription of conservative therapy for at least 6 months. 9. Ability to safely undergo liposuction that will result in the harvest of a sufficient quantity of adipose tissue (approximately 300 mL) 10. On stable regimen of one analgesic medication (rescue medication) for their knee pain due to osteoarthritis and ability and willingness to use the same analgesic medication during the study (screening period through to final study visit). 11. Ability to perform procedures required of the pain index evaluations (unassisted walking 50 feet on a flat surface and going up and down stairs) Exclusion Criteria: 1. Any major injury to the target knee within the 12 months prior to the screening visit 2. Need for cane or other assistance device for walking 3. Any surgery to the target knee within the 6 months prior to the screening visit, or surgery to the contralateral knee or other weight-bearing joint if it will interfere with knee assessments 4. Prior articular transplant procedures 5. Prior ligament reconstruction to the target knee within 12 months prior to the screening visit 6. Inflammatory arthropathies such as rheumatoid arthritis, lupus arthropathy, or psoriatic arthritis 7. Gout or calcium pyrophosphate (pseudogout) diseases that have flared within the previous 6 months prior to the screening visit 8. X-ray findings of acute fractures, known severe loss of bone density (as determined by the investigator), avascular necrosis, and/or severe bone or joint deformity in the target knee (>5 degree valgus or varus deviation from mechanical axis) 9. Fibromyalgia, pes anserine bursitis, lumbar radiculopathy, and/or neurogenic or vascular claudication 10. Primary knee pain due to diagnosed isolated patella-femoral arthritis or chondromalacia in the target knee 11. Significant target knee joint infection or skin disorder/infection within the previous 6 months prior to the screening visit 12. Symptomatic OA of the hips, spine, or ankle, if it would interfere with the evaluation of the target knee 13. Any condition requiring immunosuppressive medication or use of systemic steroids 14. Intra-articular injection of steroids in previous 3 months or hyaluronic acid in previous 6 months in one or both knees prior to the screening visit 15. Patients that have received PRP, other platelet-based product, or investigational treatment in another cell/biologic study for the targeted treatment injury in the 12 months prior to the injection procedure 16. Participation in any experimental drug or device study within the 6 months prior to the screening visit 17. Obesity defined as BMI > 35 kg/m2

Additional Information

Official title Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study
Description The ACT - OA Knee Clinical Trial is a prospective, randomized, multi-center device trial intended to assess safety and feasibility of intraarticular administration of Celution processed Adipose Derived Regenerative Cells (ADRCs). The study will include 90 patients in up to 15 sites in the United States. Subjects that have chronic knee pain due to idiopathic osteoarthritis of the knee (confirmed clinically and radiologically) will be evaluated for eligibility in this study. Following informed consent and screening evaluations, eligible subjects will undergo pre-operative testing. Subjects will then undergo fat harvest through small volume liposuction under local anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs for immediate intraarticular administration. A dose escalation approach has been designed wherein the study is divided into two double-blind, randomized, placebo-controlled parts as follows: Part A: Low Dose (20,000,000 cells): 30 patients OR Placebo: 15 patients Part B: High Dose (40,000,000 cells): 30 patients OR Placebo: 15 patients Subjects randomized to placebo will undergo fat harvest and intraarticular injection of a placebo that has been visually matched to the active test substance. All subjects will undergo imaging studies, clinical evaluations, and laboratory testing prior to and after the procedure; patients will be followed for 48 weeks after intraarticular injections are performed.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Cytori Therapeutics.